Published in:
01-03-2009 | Research Article
Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts
Authors:
Shiloh M. Martin, Robert T. O’Donnell, David L. Kukis, Craig K. Abbey, Hayes McKnight, Julie L. Sutcliffe, Joseph M. Tuscano
Published in:
Molecular Imaging and Biology
|
Issue 2/2009
Login to get access
Abstract
Purpose
The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu-DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ).
Procedures
Mice bearing human non-Hodgkin’s lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7.
Results
64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24–48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate.
Conclusions
These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.